arrow
J

Jeong‐Ok Lee

Seoul National University Bundang Hospital
H指数:30
被引数:3,501
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis

自体干细胞移植治疗原发性中枢神经系统淋巴瘤中硫替派、白消安和环磷酰胺与白消安和硫替派预处理方案的比较:一项多中心回顾性分析

2026-09-080
OAAI
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital

在三级教学医院中针对老年癌症患者开展肿瘤-老年干预模型的可行性初步研究

2026-01-010
OA
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma

早期生长反应1作为PD-L1表达和免疫逃逸的关键调节因子在结外NK/T细胞淋巴瘤中的作用

2025-06-130
OAAI
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study

TP53突变状态与性别对接受免疫检查点抑制剂治疗的非小细胞肺癌患者临床结局的影响:一项回顾性队列研究

2025-01-151
OA
PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

PHI-101,一种新型FLT3 TKI,在FLT3突变型复发性/难治性AML中显示出临床疗效

BLOOD
IF23.1
2024-11-050
PRE
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

阿卡拉布替尼联合来那度胺和利妥昔单抗治疗复发/难治性侵袭性b细胞非霍奇金淋巴瘤的单臂II期临床试验

2024-03-303
OAAI
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation
2023-06-262
OAAI
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
2023-01-130
PRE
Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study

序贯根除幽门螺杆菌治疗中度血小板减少症患者免疫性血小板减少症: 一项多中心前瞻性随机3期研究

2022-05-284
PRE